Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâ€™s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

11-05 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
07/09/26	SEK 0.1406	+9.16%	46,208

Delayed Quote London S.E.

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - London S.E. 15:45:34 03/11/2025 GMT			After hours 16:25:00
31.92 ^SEK	-32.03%		0.1580	-99.51%

09-03	Six stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-01	17 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

Market Cap	96.06M 9.84M 8.52M 8.04M 7.3M 13.69M 943M 13.79M 37.01M 478M 36.94M 36.13M 1.52B	P/E 2026 *	-1.43x	P/E 2027 *	-3.57x
Enterprise Value	61.06M 6.25M 5.42M 5.11M 4.64M 8.7M 599M 8.76M 23.53M 304M 23.48M 22.96M 966M	EV / Sales 2026 *	19.1x	EV / Sales 2027 *	3.82x
Free-Float	90.23%	Yield 2026 *	-	Yield 2027 *	-

09-03	Six stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-01	17 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
08-27	Nine stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
08-18	Seven stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
08-13	Immunovia: Strong demand for blood test for pancreatic cancer, survey shows	FW
08-07	Immunovia AB, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Immunovia increased revenue and reduced its net loss	FW
08-06	Calendar, Thursday, August 6	FW
08-05	Calendar Thursday, August 6	FW
06-15	Immunovia Unveils New Data Ahead of Medicare Reimbursement Application	FW
06-15	Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage	CI
06-10	Immunovia: Published study bolsters evidence for PancreaSure	FW

26/02/25	Carlsquare initiates assignment monitoring of Immunovia	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

Immunovia AB Share Price London S.E.

Stocks

0G8X

SE0006091997

Advanced Medical Equipment & Technology

Valuation: Immunovia AB

Chart: Immunovia AB

Latest news: Immunovia AB

Last Transcript: Immunovia AB

Analysts' recommendations: Immunovia AB

Press Releases: Immunovia AB

Quotes and Performance

Price Extremes

Managers and Directors: Immunovia AB

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-13	Immunovia presents survey data showing strong patient support for blood-based tests to detect pancreatic cancer at an earlier stage	AQ
08-06	Immunovia Publishes Interim Report for April-June 2026	AQ
08-03	Immunovia invites to a presentation on the Q2 report 2026	AQ
06-15	Immunovia announces new performance data for PancreaSure ahead of upcoming application for Medicare coverage	AQ
06-10	Immunovia publishes final AFFIRM study results in Journal of Clinical Oncology confirming strong diagnostic performance of PancreaSure	AQ

1 day	-32.03%
1 week	+24,682.61%
Current month	+22,996.96%
1 month	+18,809.95%
3 months	+17,400.00%
6 months	+19,603.70%
Current year	+13,658.62%

1 month	0.13	0.32
Current year	0.13	0.32
1 year	0.13	0.7
3 years	0.13	2.78
5 years	0.13	131.5
10 years	0.13	292

Manager	Title	Age	Since
Jeff Borcherding CEO	Chief Executive Officer	53	28/04/2023
Lisa Ford CTO	Chief Tech/Sci/R&D Officer	55	28/04/2024
Norma Alonzo Palma CTO	Chief Tech/Sci/R&D Officer	54	30/01/2024

Director	Title	Age	Since
Hans Olof Gunnar Johansson BRD	Director/Board Member	72	08/12/2016
Peter Andersen CHM	Chairman	69	25/05/2023
Martin Brygger Møller BRD	Director/Board Member	51	31/12/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOVIA AB	-32.03%	+24,682.61%	-	-	9.91M
SARTORIUS AG	-2.15%	-2.48%	+15.13%	-33.42%	16.73B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+1.03%	+6.31%	-34.38%	+45.06%	1.75B
ECKERT & ZIEGLER SE	+0.41%	-1.83%	-28.49%	+22.12%	893M
QUIDELORTHO CORPORATION	-2.89%	-14.09%	-60.25%	-84.95%	808M
VAREX IMAGING CORPORATION	+0.14%	-0.03%	+61.02%	-2.51%	778M
CONTEC MEDICAL SYSTEMS CO.,LTD	+0.19%	-4.99%	-38.74%	-49.84%	637M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	+1.76%	-8.00%	-42.32%	-51.29%	560M
REVENIO GROUP OYJ	-0.90%	-12.45%	-43.86%	-39.58%	450M
CELLAVISION AB	-0.25%	-0.62%	-8.52%	-4.73%	397M
Average	-3.25%	-5.46%	-20.05%	-22.13%	2.56B
Weighted average by Cap.	-1.39%	-2.59%	+4.12%	-26.57%

	2026 *	2027 *
Net sales	3.2M 328K 284K 268K 243K 456K 31.41M 459K 1.23M 15.93M 1.23M 1.2M 50.65M	17.3M 1.77M 1.53M 1.45M 1.31M 2.47M 170M 2.48M 6.67M 86.13M 6.65M 6.51M 274M
Net income	-87M -8.91M -7.72M -7.28M -6.61M -12.4M -854M -12.49M -33.52M -433M -33.46M -32.72M -1.38B	-76M -7.78M -6.74M -6.36M -5.77M -10.83M -746M -10.91M -29.29M -378M -29.23M -28.58M -1.2B
Net Debt	-35M -3.58M -3.11M -2.93M -2.66M -4.99M -343M -5.02M -13.49M -174M -13.46M -13.16M -554M	-30M -3.07M -2.66M -2.51M -2.28M -4.27M -294M -4.31M -11.56M -149M -11.54M -11.28M -475M